# US 2024/0199695 A1 · Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0199695 A1
- Document ID: US20240199695A1
- Status: Published application
- Kind: A1
- Application number: 18/240,295
- Filed: 2023-08-30
- Published: 2024-06-20
- Earliest claimed: 2015-11-24
- Assignees: Transfert Plus, S.E.C.
- Applicants: Transfert Plus, S.E.C.
- Inventors: Richard BÉLIVEAU; Borhane ANNABI; Michel DEMEULE; Alain LAROCQUE; Jean-Christophe CURRIE; Cyndia CHARFI
- Web page: https://patentgrep.com/patent/US20240199695A1

## CPC

- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- A61K 31/337: having four-membered rings, e.g. taxol
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- C07D 305/14: condensed with carbocyclic rings or ring systems
- C07K 1/061: {using protecting groups}
- C07K 7/083: {Neurotensin}
- C07K 14/001: {by chemical synthesis}
- C07K 14/4703: {Inhibitors; Suppressors}
- A61K 9/5107: {Excipients; Inactive ingredients}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- Y02P 20/55: Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- Y02P: CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS

## Abstract

The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula (SEQ ID NO: 1) X1X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 2) (X9)nGVX10AKAGVX11NX12FKSESY (II) (SEQ ID NO: 3) YKX13LRRX14APRWDX15PLRDPALRX16X17L (III) (SEQ ID NO: 4) YKX18LRR(X19)nPLRDPALRX20X21L (IV) (SEQ ID NO: 5) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 7) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 8) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 9) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 10) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 11) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 13) YKSLRRKAPRWDAYLRDPALRPLL (XIII) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

## Claims

### Claim at position 1

1-99. (canceled)

### Claim 100

A conjugate compound having the formula of A-(B)n,
wherein:
n is 1, 2, 3 or 4;
A is a peptide compound; and
B is a therapeutic agent, wherein B is connected to A, (i) at a free amine of said peptide compound, (ii) at an N-terminal position of said peptide compound, (iii) at a free —SH of said peptide compound, (iv) at a free carboxyl of said peptide compound, or (v) any combination of (i) to (iv);
the peptide compound is a compound chosen from compounds of formula (I), formula (II), formula (III), formula (IV), formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), formula (XII) and formula (XIII), and if chosen from compounds of formulas (V) through (XIII) the peptide compound has at least 80% sequence identity to those compounds:
X1X2X3X4X5GVX6AKAGVX7NX8FKSESY
(SEQ ID NO: 1)
(I)
(X9)nGVX10AKAGVX11NX12FKSESY
(SEQ ID NO: 2)
(II)
YKX13LRRX14APRWDX15PLRDPALRX16X17L
(SEQ ID NO: 3)
(III)
YKX18LRR(X19)nPLRDPALRX20X21L
(SEQ ID NO: 4)
(IV)
IKLSGGVQAKAGVINMDKSESM
(SEQ ID NO: 5)
(V)
IKLSGGVQAKAGVINMFKSESY
(SEQ ID NO: 6)
(VI)
IKLSGGVQAKAGVINMFKSESYK
(SEQ ID NO: 7)
(VII)
GVQAKAGVINMFKSESY
(SEQ ID NO: 8)
(VIII)
GVRAKAGVRNMFKSESY
(SEQ ID NO: 9)
(IX)
GVRAKAGVRN(Nle)FKSESY
(SEQ ID NO: 10)
(X)
YKSLRRKAPRWDAPLRDPALRQLL
(SEQ ID NO: 11)
(XI)
YKSLRRKAPRWDAYLRDPALRQLL
(SEQ ID NO: 12)
(XII)
YKSLRRKAPRWDAYLRDPALRPLL
(SEQ ID NO: 13)
(XIII)
wherein
X1, X2, X3, X4, X5, X6, X1, X8, X9, X10, X11, X12, X13, X14, X15, X18 and X19 are independently chosen from any amino acid;
X16, X17, X20 and X21 are independently chosen from Q, P, Y, I and L;
m is 0, 1, 2, 3, 4 or 5;
when X9 is present more than once, each of said X9 is independently chosen from any amino acid;
when X19 is present more than once, each of said X19 is independently chosen from any amino acid;
wherein a cysteine residue is added to said peptide compound at an N- and/or C-terminal end;
wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end; and
wherein B is connected to A via a linker.

### Claim 101 (depends on 100)

The conjugate compound of claim 100, wherein the peptide compound is represented by formula (X) (SEQ ID NO: 10) with a cysteine residue added at an N- and/or C-terminal end.

### Claim 102 (depends on 100)

The conjugate compound of claim 100, wherein the peptide compound is represented by formula (XI) (SEQ ID NO: 11) with a cysteine residue added at an N- and/or C-terminal end.

### Claim 103 (depends on 100)

The conjugate compound of claim 100, wherein the peptide compound has at least 90% sequence identity to the compound chosen from compounds of formula (V), formula (VI), formula (VII), formula (VIII), formula (IX), formula (X), formula (XI), formula (XII) and formula (XIII).

### Claim 104 (depends on 100)

The conjugate compound of claim 100, wherein the peptide compound comprises at least one protecting group that is acetyl or succinyl.

### Claim 105 (depends on 100)

The conjugate compound of claim 100, wherein the peptide compound is represented by Formula (XXXVIII), Formula (XXXIX), Formula (XXXX), Formula (XXXXI) or Formula (XXXXII), with a cysteine residue added at the C-terminal end to each of (XXXVIII)-(XXXXII):
(SEQ ID NO: 14)
Acetyl-GVRAKAGVRNMFKSESY;
(XXXVIII)
(SEQ ID NO: 15)
Acetyl-GVRAKAGVRN(Nle)FKSESY;
(XXXIX)
(SEQ ID NO: 16)
Acetyl-YKSLRRKAPRWDAPLRDPALRQLL;
(XXXX)
(SEQ ID NO: 17)
Acetyl-YKSLRRKAPRWDAYLRDPALRQLL;
(XXXXI)
(SEQ ID NO: 18)
Acetyl-YKSLRRKAPRWDAYLRDPALRPLL.
(XXXXII)

### Claim 106 (depends on 100)

The conjugate compound of claim 100, wherein B is connected to A at a free —SH of said peptide compound.

### Claim 107 (depends on 100)

The conjugate compound of claim 100, wherein the therapeutic agent is an anticancer agent.

### Claim 108 (depends on 107)

The conjugate compound of claim 107, wherein the anticancer agent is docetaxel, cabazitaxel, paclitaxel, doxorubicin, daunomycin, maytansine, or a camptothecin.

### Claim 109 (depends on 100)

A method of selectively targeting a therapeutic agent to a sortilin-expressing cell in a population of cells, comprising contacting the conjugate compound of claim 100 with the population of cells.

### Claim 110 (depends on 109)

The method of claim 109, wherein the therapeutic agent is an anticancer agent and the sortilin-expressing cell is a cancer cell.

### Claim 111

A peptide compound having: at least 92% sequence identity to a compound of formula (VI), at least 80% sequence identity to a compound of formula (X), or at least 85% sequence identity to a compound of formula (XI):
(SEQ ID NO: 6)
IKLSGGVQAKAGVINMFKSESY
(VI)
(SEQ ID NO: 10)
GVRAKAGVRN(Nle)FKSESY
(X)
(SEQ ID NO: 11)
YKSLRRKAPRWDAPLRDPALRQLL
(XI)
wherein a cysteine residue is added to said peptide compound at an N- and/or C-terminal end; and
wherein at least one protecting group and/or at least one agent is optionally connected to said peptide compound at an N-terminal position of said peptide compound, at a C-terminal position of said peptide compound, at a free amine of said peptide compound, at a free —SH of said peptide compound, or at a free carboxyl of said peptide compound.

### Claim 112 (depends on 111)

The peptide compound of claim 111, wherein the peptide compound is represented by any of formulas (VI)-(IX), (XII) and (XIII) (SEQ ID NOs: 6-9, 12 and 13) with a cysteine residue added at an N- and/or C-terminal end.

### Claim 113 (depends on 111)

The peptide compound of claim 111, wherein the peptide compound is represented by formula (X) (SEQ ID NO: 10) with a cysteine residue added at an N- and/or C-terminal end.

### Claim 114 (depends on 111)

The peptide compound of claim 111, wherein the peptide compound is represented by formula (XI) (SEQ ID NO: 11) with a cysteine residue added at an N- and/or C-terminal end.

### Claim 115 (depends on 111)

The peptide compound of claim 111, wherein the peptide compound has at least 90% sequence identity to the compound of formula (X) or formula (XI).

### Claim 116 (depends on 111)

The peptide compound of claim 111, wherein the at least one protecting group is acetyl or succinyl.

### Claim 117 (depends on 111)

The peptide compound of claim 111, wherein the peptide compound is represented by Formula (XXXVIII), Formula (XXXIX), Formula (XXXX), Formula (XXXXI) or Formula (XXXXII), with a cysteine residue added at the C-terminal end to each of (XXXVIII)-(XXXXII):
(SEQ ID NO: 14)
Acetyl-GVRAKAGVRNMFKSESY
(XXXVIII)
(SEQ ID NO: 15)
Acetyl-GVRAKAGVRN(Nle)FKSESY
(XXXIX)
(SEQ ID NO: 16)
Acetyl-YKSLRRKAPRWDAPLRDPALRQLL
(XXXX)
(SEQ ID NO: 17)
Acetyl-YKSLRRKAPRWDAYLRDPALRQLL
(XXXXI)
(SEQ ID NO: 18)
Acetyl-YKSLRRKAPRWDAYLRDPALRPLL
(XXXXII)

### Claim 118 (depends on 111)

The peptide compound of claim 111, wherein the agent is connected to said peptide compound at a free —SH of said peptide compound.

### Claim 119 (depends on 111)

A method of selectively targeting an agent to a sortilin-expressing cell in a population of cells, comprising contacting the peptide compound of claim 111 with the population of cells.
